This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): MDX-1379
Description: MDX-1379 is a vaccine consisting of two melanoma peptides derived from the cell surface protein gp100. gp100 is a protein normally found on pigmented skin cells (melanocytes), and is also present on melanoma cells. These melanoma peptides are recognized by cytotoxic T cells in melanoma patients that are positive for HLA-A2, a human immune system compatibility antigen that is expressed in approximately half of the melanoma population.
Deal Structure: Bristol-Myers Squibb Company and Medarex announced on 1/13/05 that the global development and commercialization collaboration agreement, previously announced by both companies on 11/8/04, had become effective.
The collaboration includes MDX-1379, which will be developed for potential use in combination with MDX-010 in melanona.
Medarex will receive an initial cash payment of $50 million, of which $25 million will be for a purchase of Medarex's common stock by Bristol-Myers Squibb. In addition, Medarex could receive up to $205 million if all regulatory milestones are met, and up to $275 million in sales- related milestones. Medarex has an option to co-promote and share profits with Bristol-Myers Squibb in the United States. Bristol-Myers Squibb will receive an exclusive license outside of the United States and will pay royalties to Medarex on any commercial sales.
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement...See full deal structure in Biomedtracker
Additional information available to subscribers only: